Vanguard Group Inc. lifted its holdings in shares of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) by 16.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,208,139 shares of the biopharmaceutical company’s stock after acquiring an additional 1,027,515 shares during the quarter. Vanguard Group Inc. owned 15.99% of Peregrine Pharmaceuticals worth $4,382,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Ballentine Partners LLC purchased a new stake in shares of Peregrine Pharmaceuticals during the second quarter valued at approximately $113,000. Bank of New York Mellon Corp increased its position in shares of Peregrine Pharmaceuticals by 1.9% during the first quarter. Bank of New York Mellon Corp now owns 198,296 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 3,732 shares during the last quarter. KCG Holdings Inc. increased its position in shares of Peregrine Pharmaceuticals by 941.5% during the first quarter. KCG Holdings Inc. now owns 238,906 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 215,967 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Peregrine Pharmaceuticals by 48.0% during the second quarter. Wells Fargo & Company MN now owns 338,378 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 109,750 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Peregrine Pharmaceuticals by 9.3% during the second quarter. Northern Trust Corp now owns 454,451 shares of the biopharmaceutical company’s stock valued at $276,000 after acquiring an additional 38,604 shares during the last quarter. 18.88% of the stock is owned by institutional investors.
PPHM has been the subject of a number of research analyst reports. Zacks Investment Research raised Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. Noble Financial started coverage on Peregrine Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st.
Peregrine Pharmaceuticals Inc. (NASDAQ PPHM) opened at $5.20 on Friday. Peregrine Pharmaceuticals Inc. has a twelve month low of $1.96 and a twelve month high of $5.78.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its quarterly earnings data on Monday, September 11th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. The business had revenue of $27.08 million during the quarter, compared to analyst estimates of $15.22 million. research analysts forecast that Peregrine Pharmaceuticals Inc. will post -0.43 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/02/peregrine-pharmaceuticals-inc-pphm-shares-bought-by-vanguard-group-inc.html.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Want to see what other hedge funds are holding PPHM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM).
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.